レミケードの市場規模、シェア、動向分析レポート：タイプ別、適応症別、流通チャネル別、地域別、セグメント予測、2025年～2030年

レミケード市場の成長と動向

Grand View Research社の最新レポートによると、レミケードの世界市場規模は2030年までに26億2,000万米ドルに達すると予測され、2025年から2030年までのCAGRは-2.28%で減少すると予測されています。

ブランドの優位性は徐々に低下しているもの、レミケード（インフリキシマブ）市場は、クローン病や関節リウマチなどの自己免疫疾患の世界の負担を背景に、持続的な需要を示し続けています。レミケードは、これらの疾患に対して広く処方されている生物学的製剤であり続けています。しかし、進化する規制政策とヘルスケア費用対効果戦略に支えられ、バイオシミラーの参入と受容が増加しているため、市場は大きな変化を遂げつつあります。

市場シェアの低下は、バイオシミラー・インフリキシマブの選択肢が広がったことと密接に結びついています。主要地域で特許が満了し、特にコスト削減を求める公的ヘルスケア制度を持つ国々では、バイオシミラーがより入手しやすくなっています。この変化は、患者による治療への幅広いアクセスを促すと同時に、価格競争を激化させ、先発品の地位に課題しています。それでもなお、レミケードの豊富な臨床実績と医師による使い慣れにより、特に複雑な症例での使用が支持されています。

特に生物学的製剤の使用がまだ拡大している地域では、市場成長の機会が残されています。アジア、ラテンアメリカ、中東・アフリカの一部の市場では、ヘルスケア・インフラの改善と炎症性疾患に対する意識の高まりが、先発品生物学的製剤とバイオシミラーの両方に対する需要の増加を促しています。さらに、現在進行中の臨床研究や皮下投与を含む新しいインフリキシマブの製剤が、進化する治療状況に貢献しています。

ヤンセン、セルトリオン、ファイザーなど、レミケードに関わる製薬企業は、地域ライセンス契約、承認後の製造提携、実臨床エビデンスへの投資などの戦略で、こうしたシフトに対応しています。バイオシミラー開発企業もまた、高濃度製剤や共同販売契約などの差別化戦術を活用し、市場参入を強化しています。

レミケード市場レポートハイライト

• タイプ別では、ブランドセグメントが2024年の売上高シェア52.8%で市場をリード。この優位性は、医師の強い信頼、確立された臨床データ、特定市場でのバイオシミラー採用の遅れ、ブランドに対する患者の信頼によるものです。
• 適応症別では、関節リウマチ分野が2024年に20.8%の最大売上シェアで市場をリードしました。
• 販売チャネル別では、病院薬局部門が2024年に最大の市場売上シェアを占めました。これは、専門的治療への直接アクセス、強力な医師の推薦、複雑な自己免疫疾患の患者数の多さなどにより、病院薬局がレミケード（インフリキシマブ）の好ましい販売チャネルとなっているためです。
• 2024年3月、セルトリオンは先発医薬品であるザイムフェントラを米国市場に導入する計画を発表しました。自己免疫疾患の治療薬であるザイムフェントラの上市は、バイオシミラーにとどまらずポートフォリオを拡大するというセルトリオンの戦略における重要な一歩となります。この動きは、提供する製品を多様化し、生物学的製剤開発の専門知識を新たな治療領域に活用するという同社の広範な戦略を反映したものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 レミケード市場の変数、動向、範囲

• 市場系統の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 業界分析- ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析
  • 特許満了分析
  • 価格分析

第4章 レミケード市場：タイプ別ビジネス分析

• タイプ別市場シェア、2024年と2030年
• タイプ別セグメントダッシュボード
• 市場規模、予測、動向分析（タイプ別、2018～2030年）
• ブランド
• バイオシミラー

第5章 レミケード市場：適応症別ビジネス分析

• 適応症別市場シェア、2024年および2030年
• 適応症別セグメントダッシュボード
• 市場規模、予測、動向分析（適応症別、2018～2030年）
• 関節リウマチ
• 乾癬性関節炎
• クローン病
• 潰瘍性大腸炎
• 強直性脊椎炎
• その他

第6章 レミケード市場：流通チャネル別ビジネス分析

• 流通チャネル別市場シェア、2024年および2030年
• 流通チャネル別セグメントダッシュボード
• 市場規模、予測、動向分析（流通チャネル別、2018～2030年）
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 レミケード市場：地域推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域別市場ダッシュボード
• 市場規模と予測動向分析、2018年から2030年まで：
• 北米
  • 国別、2018年～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東およびアフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/リスト
  • Janssen Pharmaceuticals（Johnson &Johnson）;
  • Celltrion
  • Pfizer Inc.
  • Boehringer Ingelheim Pharmaceuticals Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc.
  • Samsung Bioepis

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. Global Remicade market, by region, 2018 - 2030 (USD Million)
• Table 4. Global Remicade market, by type, 2018 - 2030 (USD Million)
• Table 5. Global Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 6. Global Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 7. North America Remicade market, by country, 2018 - 2030 (USD Million)
• Table 8. North America Remicade market, by type, 2018 - 2030 (USD Million)
• Table 9. North America Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 10. North America Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 11. U.S. Remicade market, by type, 2018 - 2030 (USD Million)
• Table 12. U.S. Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 13. U.S. Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 14. Canada Remicade market, by type, 2018 - 2030 (USD Million)
• Table 15. Canada Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 16. Canada Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 17. Mexico Remicade market, by type, 2018 - 2030 (USD Million)
• Table 18. Mexico Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 19. Mexico Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 20. Europe Remicade market, by country, 2018 - 2030 (USD Million)
• Table 21. Europe Remicade market, by type, 2018 - 2030 (USD Million)
• Table 22. Europe Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 23. Europe Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 24. UK Remicade market, by type, 2018 - 2030 (USD Million)
• Table 25. UK Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 26. UK Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 27. Germany Remicade market, by type, 2018 - 2030 (USD Million)
• Table 28. Germany Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 29. Germany Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 30. France Remicade market, by type, 2018 - 2030 (USD Million)
• Table 31. France Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 32. France Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 33. Italy Remicade market, by type, 2018 - 2030 (USD Million)
• Table 34. Italy Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 35. Italy Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 36. Spain Remicade market, by type, 2018 - 2030 (USD Million)
• Table 37. Spain Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 38. Spain Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 39. Norway Remicade market, by type, 2018 - 2030 (USD Million)
• Table 40. Norway Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 41. Norway Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 42. Denmark Remicade market, by type, 2018 - 2030 (USD Million)
• Table 43. Denmark Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 44. Denmark Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 45. Sweden Remicade market, by type, 2018 - 2030 (USD Million)
• Table 46. Sweden Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 47. Sweden Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 48. Asia Pacific Remicade market, by country, 2018 - 2030 (USD Million)
• Table 49. Asia Pacific Remicade market, by type, 2018 - 2030 (USD Million)
• Table 50. Asia Pacific Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 51. Asia Pacific Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 52. Japan Remicade market, by type, 2018 - 2030 (USD Million)
• Table 53. Japan Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 54. Japan Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 55. China Remicade market, by type, 2018 - 2030 (USD Million)
• Table 56. China Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 57. China Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 58. India Remicade market, by type, 2018 - 2030 (USD Million)
• Table 59. India Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 60. India Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 61. Australia Remicade market, by type, 2018 - 2030 (USD Million)
• Table 62. Australia Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 63. Australia Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 64. South Korea Remicade market, by type, 2018 - 2030 (USD Million)
• Table 65. South Korea Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 66. South Korea Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 67. Thailand Remicade market, by type, 2018 - 2030 (USD Million)
• Table 68. Thailand Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 69. Thailand Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 70. Latin America Remicade market, by country, 2018 - 2030 (USD Million)
• Table 71. Latin America Remicade market, by type, 2018 - 2030 (USD Million)
• Table 72. Latin America Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 73. Latin America Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 74. Brazil Remicade market, by type, 2018 - 2030 (USD Million)
• Table 75. Brazil Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 76. Brazil Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 77. Argentina Remicade market, by type, 2018 - 2030 (USD Million)
• Table 78. Argentina Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 79. Argentina Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 80. Middle East & Africa Remicade market, by country, 2018 - 2030 (USD Million)
• Table 81. Middle East & Africa Remicade market, by type, 2018 - 2030 (USD Million)
• Table 82. Middle East & Africa Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 83. Middle East & Africa Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 84. South Africa Remicade market, by type, 2018 - 2030 (USD Million)
• Table 85. South Africa Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 86. South Africa Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 87. Saudi Arabia Remicade market, by type, 2018 - 2030 (USD Million)
• Table 88. Saudi Arabia Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 89. Saudi Arabia Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 90. UAE Remicade market, by type, 2018 - 2030 (USD Million)
• Table 91. UAE Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 92. UAE Remicade market, by distribution channel, 2018 - 2030 (USD Million)
• Table 93. Kuwait Remicade market, by type, 2018 - 2030 (USD Million)
• Table 94. Kuwait Remicade market, by indication, 2018 - 2030 (USD Million)
• Table 95. Kuwait Remicade market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Remicade market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Therapeutic approach and indication outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 Remicade market dynamics
• Fig. 12 Remicade market: Porter's five forces analysis
• Fig. 13 Remicade market: PESTLE analysis
• Fig. 14 Type market, 2018 - 2030 (USD Million)
• Fig. 15 Branded market, 2018 - 2030 (USD Million)
• Fig. 16 Biosimilar market, 2018 - 2030 (USD Million)
• Fig. 17 Indication market, 2018 - 2030 (USD Million)
• Fig. 18 Rheumatoid Arthritis market, 2018 - 2030 (USD Million)
• Fig. 19 Psoriatic Arthritis market, 2018 - 2030 (USD Million)
• Fig. 20 Crohn's Diseases market, 2018 - 2030 (USD Million)
• Fig. 21 Ulcerative Colitis market, 2018 - 2030 (USD Million)
• Fig. 22 Ankylosing Spondylitis market, 2018 - 2030 (USD Million)
• Fig. 23 Others market, 2018 - 2030 (USD Million)
• Fig. 24 Distribution Channel market, 2018 - 2030 (USD Million)
• Fig. 25 Hospital Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 26 Retail Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 27 Online Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 28 Remicade market revenue, by region
• Fig. 29 Regional marketplace: Key takeaways
• Fig. 30 Regional marketplace: Key takeaways
• Fig. 31 North America Remicade market, 2018 - 2030 (USD Million)
• Fig. 32 US country dynamics
• Fig. 33 US Remicade market, 2018 - 2030 (USD Million)
• Fig. 34 Canada country dynamics
• Fig. 35 Canada Remicade market, 2018 - 2030 (USD Million)
• Fig. 36 Mexico country dynamics
• Fig. 37 Mexico Remicade market, 2018 - 2030 (USD Million)
• Fig. 38 Europe Remicade market, 2018 - 2030 (USD Million)
• Fig. 39 UK country dynamics
• Fig. 40 UK Remicade market, 2018 - 2030 (USD Million)
• Fig. 41 Germany country dynamics
• Fig. 42 Germany Remicade market, 2018 - 2030 (USD Million)
• Fig. 43 France country dynamics
• Fig. 44 France Remicade market, 2018 - 2030 (USD Million)
• Fig. 45 Italy country dynamics
• Fig. 46 Italy Remicade market, 2018 - 2030 (USD Million)
• Fig. 47 Spain country dynamics
• Fig. 48 Spain Remicade market, 2018 - 2030 (USD Million)
• Fig. 49 Norway country dynamics
• Fig. 50 Norway Remicade market, 2018 - 2030 (USD Million)
• Fig. 51 Sweden country dynamics
• Fig. 52 Sweden Remicade market, 2018 - 2030 (USD Million)
• Fig. 53 Denmark country dynamics
• Fig. 54 Denmark Remicade market, 2018 - 2030 (USD Million)
• Fig. 55 Asia Pacific Remicade market, 2018 - 2030 (USD Million)
• Fig. 56 Japan country dynamics
• Fig. 57 Japan Remicade market, 2018 - 2030 (USD Million)
• Fig. 58 China country dynamics
• Fig. 59 China Remicade market, 2018 - 2030 (USD Million)
• Fig. 60 India country dynamics
• Fig. 61 India Remicade market, 2018 - 2030 (USD Million)
• Fig. 62 Australia country dynamics
• Fig. 63 Australia Remicade market, 2018 - 2030 (USD Million)
• Fig. 64 South Korea country dynamics
• Fig. 65 South Korea Remicade market, 2018 - 2030 (USD Million)
• Fig. 66 Thailand country dynamics
• Fig. 67 Thailand Remicade market, 2018 - 2030 (USD Million)
• Fig. 68 Latin America Remicade market, 2018 - 2030 (USD Million)
• Fig. 69 Brazil country dynamics
• Fig. 70 Brazil Remicade market, 2018 - 2030 (USD Million)
• Fig. 71 Argentina country dynamics
• Fig. 72 Argentina Remicade market, 2018 - 2030 (USD Million)
• Fig. 73 MEA Remicade market, 2018 - 2030 (USD Million)
• Fig. 74 South Africa country dynamics
• Fig. 75 South Africa Remicade market, 2018 - 2030 (USD Million)
• Fig. 76 Saudi Arabia country dynamics
• Fig. 77 Saudi Arabia Remicade market, 2018 - 2030 (USD Million)
• Fig. 78 UAE country dynamics
• Fig. 79 UAE Remicade market, 2018 - 2030 (USD Million)
• Fig. 80 Kuwait country dynamics
• Fig. 81 Kuwait Remicade market, 2018 - 2030 (USD Million)
• Fig. 82 Company categorization
• Fig. 83 Company market position analysis
• Fig. 84 Strategic framework

Remicade Market Growth & Trends:

The global remicade market size is anticipated to reach USD 2.62 billion by 2030 and is projected to decline at a CAGR of -2.28% from 2025 to 2030, according to a new report by Grand View Research, Inc. Despite a gradual decline in brand dominance, the Remicade (infliximab) market continues to show sustained demand, driven by the global burden of autoimmune diseases such as Crohn's disease and rheumatoid arthritis. Remicade has remained a widely prescribed biologic for these conditions. However, the market is undergoing significant change due to the increasing entry and acceptance of biosimilars, supported by evolving regulatory policies and healthcare cost-effective strategies.

The decline in market share is closely tied to the broader availability of biosimilar infliximab options. With patents expiring in key regions, biosimilars have become more accessible, particularly in countries with public healthcare systems seeking cost savings. This shift is encouraging broader patient access to treatment while intensifying price competition, challenging the position of the original product. Still, Remicade's extensive clinical history and physician familiarity support its use, especially in complex cases.

Opportunities for market growth remain, especially in regions where biologic use is still expanding. In markets across Asia, Latin America, and parts of the Middle East and Africa, improvements in healthcare infrastructure and rising awareness of inflammatory diseases are driving increased demand for both originator biologics and biosimilars. Moreover, ongoing clinical research and new infliximab formulations, including subcutaneous delivery, contribute to the evolving therapeutic landscape.

Pharmaceutical companies involved in the Remicade industry, including Janssen, Celltrion, and Pfizer, are responding to these shifts with strategies such as regional licensing deals, post-approval manufacturing partnerships, and investment in real-world evidence. Biosimilar developers also leverage differentiation tactics, including high-concentration formulations and co-marketing agreements, to strengthen market entry.

Remicade Market Report Highlights:

• Based on type, the branded segment led the market with the largest revenue share of 52.8% in 2024. This dominance is attributable to strong physician trust, established clinical data, slower biosimilar adoption in certain markets, and patient trust in the brand.
• Based on indication, the rheumatoid arthritis segment led the market with the largest revenue share of 20.8% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies.
• Based on distribution channel, the hospital pharmacies segment accounted for the largest market revenue share in 2024, due to their direct access to specialized treatments, strong physician recommendations, and higher patient volumes for complex autoimmune conditions, making them the preferred distribution channel for Remicade (infliximab).
• In March 2024, Celltrion announced plans to introduce its original drug, Zymfentra, to the U.S. market. The launch of Zymfentra, a treatment for autoimmune diseases, marks a significant step in Celltrion's strategy to expand its portfolio beyond biosimilars. This move reflects the company's broader strategy to diversify its offerings and leverage its expertise in biologic drug development for new therapeutic areas.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Indication
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Remicade Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Remicade Market: Type Business Analysis

• 4.1. Type Market Share, 2024 & 2030
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Branded
  • 4.4.1. Branded Market, 2018 - 2030 (USD Million)
• 4.5. Biosimilar
  • 4.5.1. Biosimilar Market, 2018 - 2030 (USD Million)

Chapter 5. Remicade Market: Indication Business Analysis

• 5.1. Indication Market Share, 2024 & 2030
• 5.2. Indication Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 5.4. Rheumatoid Arthritis
  • 5.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
• 5.5. Psoriatic Arthritis
  • 5.5.1. Psoriatic Arthritis Market, 2018 - 2030 (USD Million)
• 5.6. Crohn's Disease
  • 5.6.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
• 5.7. Ulcerative Colitis
  • 5.7.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)
• 5.8. Ankylosing Spondylitis
  • 5.8.1. Ankylosing Spondylitis Market, 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Remicade Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2030
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 6.6. Online Pharmacies
  • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Remicade Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Remicade Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. Canada Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. UK Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Target Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Target Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Target Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Brazil Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. Argentina Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Target Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Target Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Target Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Target Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Janssen Pharmaceuticals (Johnson & Johnson);
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Type Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Celltrion
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Type Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Pfizer Inc.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Type Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Boehringer Ingelheim Pharmaceuticals Inc.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Type Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Novartis AG
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Type Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Teva Pharmaceutical Industries Ltd
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Type Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Pfizer Inc.
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Type Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Samsung Bioepis
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Type Benchmarking
    • 8.5.8.4. Strategic Initiatives